Therefore, the inhibition of CCR7 may potentially be used in combination with conventional chemotherapeutics in a multipronged approach to eliminate both rapidly dividing bulk tumor cells and quiescent stem-like cells. This evidence concerns the gene CCR7 and neoplasm.